Last reviewed · How we verify
VLP-Polio high dose
VLP-Polio high dose is a Biologic drug developed by CanSino Biologics Inc.. It is currently in Phase 1 development.
VLP-Polio is a recombinant trivalent poliomyelitis vaccine that is being studied for the prevention of poliomyelitis. It is a protein-based vaccine, as indicated by its modality on ChEMBL, and has been evaluated in a Phase I/II clinical trial for its safety and immunogenicity in infants and toddlers.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | VLP-Polio high dose |
|---|---|
| Sponsor | CanSino Biologics Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers (PHASE1, PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VLP-Polio high dose CI brief — competitive landscape report
- VLP-Polio high dose updates RSS · CI watch RSS
- CanSino Biologics Inc. portfolio CI
Frequently asked questions about VLP-Polio high dose
What is VLP-Polio high dose?
Who makes VLP-Polio high dose?
What development phase is VLP-Polio high dose in?
Related
- Manufacturer: CanSino Biologics Inc. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing